Compare iShares MSCI India ETF (INDA) vs Organon & Co. Common Stock (OGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MSCI India ETF vs Organon & Co. Common Stock — how do they compare? iShares MSCI India ETF trades at $47.7 (market cap $5.71B), while Organon & Co. Common Stock trades at $13.58 (market cap $3.62B). The key difference: iShares MSCI India ETF is the larger of the two by market cap, and Organon & Co. Common Stock pays a 0.58% dividend while iShares MSCI India ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold iShares MSCI India ETF for 60 Days and Organon & Co. Common Stock for 0 Days on average.
| INDA | OGN | |
|---|---|---|
Market Cap | $5.71B | $3.62B |
Volume | 3,011,243 | 2,892,999 |
Sector | Broad Market / Factor | Health |
52-Week High | $55.29 | $13.81 |
52-Week Low | $45.42 | $5.70 |
Typical Hold Time | 60 Days | 0 Days |
Enterprise Value | — | $11.04B |
Dividend Yield | — | 0.58% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INDA trades at $47.24, up 1.99% today, but technical indicators show a bearish trend with moving averages signaling sell pressure. The ETF faces headwinds from India's economic challenges including coal power shortages, below-average monsoon rains, and pharmaceutical sector export issues. Recent news highlights India's energy security concerns and IT sector weakness, creating a cautious market environment despite the country's economic growth narrative.
The outlook remains cautious with technical weakness outweighing short-term gains. Investment opportunity exists for long-term exposure to India's growth story, but risks include energy sector instability, weather-dependent agricultural output, and global trade tensions affecting key export industries.
Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.
OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About iShares MSCI India ETF
INDA tracks the MSCI India Index, providing broad exposure to large and mid-cap companies in the Indian stock market. It is structurally dominated by the financials, information technology, and energy sectors, serving as a core instrument for investors seeking a single-country view of India's long-term economic growth.
Read more on INDA →About Organon & Co. Common Stock
Organon & Co. is a global healthcare company focused on women's health, biosimilars, and established brands, spun off from Merck & Co. in 2021. Its portfolio of more than 70 medicines includes contraception and fertility therapies, immunology and oncology biosimilars, and treatments in cardiovascular, respiratory, and dermatology, distributed in over 140 countries.
Read more on OGN →
